Published in Cardiovascular Business Week, October 26th, 2004
According to the FDA approval letter, Morton Grove Pharmaceuticals' Cyclosporine Oral Solution USP, 100 mg/ml, is bioequivalent and therefore therapeutically equivalent to SandimmuneOral Solution 100 mg/ml of Novartis Pharmaceuticals Corporation.
Brian Tambi, chairman and chief executive officer said, "The approval of Cyclosporine Oral Solution is a critical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.